WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
SHANGHAI, July 29 /PRNewswire-Asia-FirstCall/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that its previously announced transaction with Charles River Laboratories International Inc. (NYSE: CRL) has been terminated by mutual agreement due to Charles River shareholder opposition. Under the terms of the termination agreement, WuXi will receive a breakup fee of $30 million. (Logo …
Go to Source